Fate Therapeutics (NASDAQ:FATE - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $1.18 million for the quarter.
Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its quarterly earnings data on Wednesday, March 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.13. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. The firm had revenue of $1.86 million for the quarter, compared to analyst estimates of $1.57 million. On average, analysts expect Fate Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Fate Therapeutics Stock Down 7.3 %
Shares of FATE stock traded down $0.09 during trading on Tuesday, reaching $1.09. 889,092 shares of the company's stock were exchanged, compared to its average volume of 2,263,647. Fate Therapeutics has a twelve month low of $0.66 and a twelve month high of $5.92. The firm's fifty day moving average price is $1.01 and its 200-day moving average price is $1.61. The stock has a market capitalization of $124.35 million, a PE ratio of -0.66 and a beta of 2.31.
Analysts Set New Price Targets
FATE has been the topic of several research analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Fate Therapeutics in a research report on Thursday, March 6th. Stifel Nicolaus lowered their price target on shares of Fate Therapeutics from $5.00 to $3.00 and set a "hold" rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company decreased their target price on Fate Therapeutics from $5.00 to $4.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Wedbush reissued a "neutral" rating and set a $5.00 price target on shares of Fate Therapeutics in a report on Thursday, March 6th. Finally, StockNews.com lowered Fate Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $5.43.
Read Our Latest Analysis on FATE
About Fate Therapeutics
(
Get Free Report)
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Featured Stories
Before you consider Fate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fate Therapeutics wasn't on the list.
While Fate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
